



Polypoidal choroidal vasculopathy (PCV) is a disease of the choroidal 
vasculature that may result in sub-retinal hemorrhage and serous detach-
ment of the retinal pigmented epithelium (RPE), leading to sub-retinal 
fibrosis and, sometimes, permanent vision loss. This report describes a 
case of PCV in an African-American female over the course of 1 year and 
demonstrates the progression of PCV, from being relatively asymptomatic 
to the development of a visually significant sub-retinal hemorrhage. She 
is currently being treated with Avastin intravitreal injections with some 
resolution of her symptoms and a reduction of sub-retinal bleeding. 
INTRODUCTION
Polypoidal choroidal vasculopathy (PCV) is a disease of the choroidal vas-
culature that includes a sub-retinal branching vascular network with in-
terconnected reddish-orange dilated vessels, which form this condition’s 
characteristic polyps. Sub-retinal hemorrhage and serous detachment of 
the retinal pigmented epithelium (RPE) may occur with this condition, 
leading to sub-retinal fibrosis and possible permanent vision loss. Pa-
tients are often asymptomatic, but may present with an acute or gradual 
decrease in vision if the macula is affected. This report describes a case 
of PCV in an African-American female as she progressed from being rela-
tively asymptomatic through the development of sub-retinal hemorrhage. 
Optical Coherence Tomography (OCT), intravenous fluorescein angiog-
raphy (IVFA), and fundus photography were used to demonstrate the 
different presentations associated with this condition and highlight the 
differences between PCV and one of its primary differential diagnoses, 
age-related macular degeneration (AMD). 
CASE REPORT
A 62-year-old African-American female presented at the eye clinic for an 
annual exam with no ocular complaints. She reported stable vision, but 
needed a new spectacle prescription for reading and night-driving. Her 
medical history consisted of asthma and gastroesophageal reflux disease 
that were being controlled with albuterol and omeprazole, respectively. 
Her ocular history consisted only of refractive error and she had no perti-
nent family ocular history. 
Uncorrected entering VA’s were OD: 20/30, PH 20/25 and OS: 20/30, 
PH 20/25. Her refraction was OD: -0.25 -0.25 x140 and OS: -0.25 -0.75 
x005 with an add of +2.50, and she was corrected to 20/20 OD, OS, and 
OU. Her pupils were equal, round, and reactive to light, and there was no 
afferent pupillary defect (APD). Ocular motilities were full and smooth 
OD, OS and her confrontation visual fields were full with finger-count-
ing in all quadrants in both eyes. Anterior slit lamp examination showed 
no remarkable findings. Goldmann applanation tonometry measured 
pressures of 17 mmHg in both eyes. Dilated fundus exam showed trace 
nuclear sclerosis of the lens in both eyes and a posterior vitreous detach-
ment in both eyes. The optic nerves had a C/D ratio of 0.5 round in both 
eyes, and were pink and distinct. The a/v ratio was 2/3 with normal cali-
ber and no crossing changes in both eyes. The maculae were flat with no 
sub-retinal fluid. The right eye showed multiple peripapillary yellow-
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orange sub-retinal clustered lesions inferior temporal to the optic nerve (Figure 1). There was a small area of 
thickening about 1 disc diameter inferior temporal to the optic nerve head in the right eye. The posterior pole 
of the left eye was normal. The peripheral retina was flat and intact in both eyes with mild areas of reticular 
changes. OCT showed a normal foveal contour and no abnormal findings in the left eye. The foveal contour of 
the right eye was normal, but there were several peripapillary RPE elevations with overlying sub-retinal fluid 
(Figures 2 and 3). After a careful review of these findings, the patient was diagnosed with polypoidal choroidal 
vasculopathy. No treatment was indicated at the time of the initial visit as there was no macular involvement. 
It was recommended that the patient be followed by a retina specialist and she had follow-ups for the next 3 
months with no change in the retina appearance, no presence of leakage as measured by IVFA and no increase 
in thickness of sub-retinal polyps as assessed by OCT. 
Figure 1: Fundus photograph of initial presentation, OD
 
Figure 2: Spectralis OCT of initial presentation, foveal cross-section
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Figure 3: Spectralis OCT of initial presentation, inferior macular cross-section
 
Approximately 4 months after the diagnosis, the patient presented at the clinic for an emergency visit with complaints of 
blurred vision and new onset of flashes and floaters in the right eye for two days. Her vision with glasses was 20/40-1 with 
eccentric viewing OD and 20/20 with the left eye. There was no improvement with refraction. Her pupils were equal, 
round, and reactive to light, and there was no APD. Ocular motilities were full and smooth OD, OS and her confrontation 
visual fields were full with finger-counting in all quadrants in both eyes. The right eye had central metamorphopsia and 
an incomplete central scotoma as measured on an Amsler grid. Anterior slit lamp examination showed no remarkable 
findings. Goldmann applanation tonometry measured pressures of 17mmHg in the right eye and 19mmHg in the left eye. 
Dilated fundus exam showed trace nuclear sclerosis of the lens in both eyes and a posterior vitreous detachment in both 
eyes. The optic nerves had a C/D ratio of 0.5 round in both eyes, and were pink and distinct. The a/v ratio was 2/3 with 
normal caliber and no crossing changes were noted in either eye. The macula and posterior pole of the left eye were flat 
without fluid. In the right eye, a large sub-retinal hemorrhage measuring 5 disc diameters (DD) horizontal by 4DD verti-
cal was present throughout the macula and inferior to the optic nerve with overlying sub-retinal fluid extending into the 
inferior arcade as viewed on clinical exam and confirmed by OCT (Figure 4). The peripheries of both the right and left 
eyes were flat and intact without breaks, holes or tears. OCT showed a large area of significant sub-retinal fluid and large 
elevations in the RPE inferior to the optic nerve extending to the macular region in the right eye (Figures 5 and 6). An 
appointment was scheduled for evaluation by a retina specialist within a week. The retina specialist initiated treatment 
with Avastin intravitreal injections. The patient returned for a follow-up appointment in our clinic four months later, 
after receiving four Avastin injections in the right eye. Her vision was corrected to 20/30 OD and 20/20 OS. All exam 
findings were stable, but she showed a significant reduction in sub-retinal fluid in the right eye (Figure 7). There was no 
sub-retinal fluid in the macular region and the sub-retinal hemorrhage had decreased substantially to a small area ap-
proximately 1DD in size (Figures 8 and 9). She has continued to be followed by a retina specialist.
Figure 4: Fundus photograph at four-month follow up
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Figure 5: Spectralis OCT at four-month follow-up, foveal cross-section
Figure 6: Spectralis OCT at three-month follow up, inferior macular cross-section
Figure 7: Fundus photograph at seven-month follow-up
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Figure 8: Spectralis OCT at eight-month follow-up, foveal cross-section
Figure 9: Spectralis OCT at seven month follow- up, inferior macular cross-section
DISCUSSION
While PCV is currently considered a variation of exudative age-related macular degeneration (AMD), some reports 
suggest that PCV may be a distinct vascular abnormality.2 Although PCV is phenotypically similar to AMD, it tends 
to have a very different natural progression, target demographic and response to treatment.2,6 PCV is more common 
in Asian and African-American populations, while AMD is more common in Caucasian patients.2,6 Different races 
tend to display different genetic markers for PCV and AMD, but risk alleles tend to be the same in both conditions, 
suggesting that the clinical appearance and efficacy of treatment for PCV may be affected by other additional genes 
or modulating factors amongst different ethnicities.1,2,6 PCV is more common among men in Asian populations (22-
37% female), but more prevalent in women in Caucasian populations (52-65% female).2 While PCV affects patients 
aged 21-93 years (mean 68.4 years), AMD is most often seen at around 80 years of age.2,6,7 Several studies have de-
termined the systemic and ocular risk factors for PCV, which include systemic hypertension, elevated C-reactive 
proteins, history of central serous chorioretinopathy and cigarette smoking.2
The clinical appearances of PCV and AMD are quite similar in some regards, but they do display some dis-
tinct variations. Both diseases show abnormal neovascularization of retinal tissues and sub-retinal fluid 
accumulation that result in sequelae such as sub-retinal hemorrhage and pigment epithelial detachment 
(PED).1 PCV has a clinical appearance that differ from that of AMD. PCV is often found in the peripapil-
lary and extramacular area whereas AMD exists exclusively within the macula.2 PCV may also be located 
outside the vascular arcades of the posterior pole.2 PCV presents with signs of a branching vascular net-
work with interconnected orange-red dilated protrusions, or polypoids, below the RPE instead of the dru-
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sen, pigment clumping and geographic atrophy seen most commonly in AMD.1 Subretinal polypoidal vascular 
structures can be associated with PED and can induce exudative changes such as serous retinal detachment 
(SRD), sub-retinal hemorrhage, and sub-retinal fibrosis.1,2 It has been reported that polyps are commonly 
present at the margins and inside the PED.2 Micro-rips, hyperplasia and atrophy of the RPE are often found 
overlying or surrounding the vascular nodules.2 Because of the variation in the locations of polypoidal le-
sions compared to AMD, the baseline mean visual acuity in PCV is, on average, better than that in AMD.2,4,7 
The presence of serous PED for longer than 12 months is a suspected risk factor for a reduction in visual acuity 
in PCV patients due to increased infiltration of the polyps into the subretinal pigment epithelial space.2
PCV is best diagnosed with indocyanine green angiography (ICGA) rather than IVFA due to its ability to image 
the choroidal circulation below the RPE.2,4 With IVFA, one cannot reliably differentiate PCV from exudative AMD 
secondary to choroidal neovascularization.4 Despite being the standard for diagnosis, ICGA is not widely used in 
countries that do not have a high prevalence of PCV.1 SD-OCT can also aid in the early detection of the disease when 
other imaging studies are not readily available.8 
Treatment strategies also differ between AMD and PCV. Research has demonstrated that the use of anti-VEGF 
therapy provides some improvement in vision in patients with PCV.1 Unlike AMD, patients with PCV have been 
shown to respond more favorably to verteporfin photodynamic therapy (PDT) after failing to respond to anti-
VEGF therapy.1,2,6 However, despite a better initial reaction to PDT, research showed that the improvement in 
VA was not significant after 12-36 months of initial treatment with PDT alone.2-4 Recent studies suggest that 
the use of PDT in conjunction with anti-VEGF therapy provides an added benefit in the treatment of PCV.1 The 
EVEREST study reported that PDT monotherapy and combination therapy (PDT + anti-VEGF) achieved high-
er proportions of patients(77.8 % and 71.4%) with complete polyp regression than anti-VEGF injection therapy 
alone (28.6%) at 6 months, but did not conclude whether monotherapy or combination therapy was better for 
visual acuity outcomes.1-4 Intravitreal injection of an anti-VEGF agent (ranibizumab or bevacizumab) remains 
a contentious treatment choice for PCV.2 More recently, the “LAPTOP” study revealed that PCV patients who 
received a series of three monthly injections followed by as-needed injections of ranibizumab had a better 
improvement of visual acuity (30.4%) than those who received PDT monotherapy (17%) at 12 and 24 months, 
though the injections did not result in complete polyp regression.2,3,9 In fact, treatment with anti-VEGF therapy 
exclusively in patients who respond favorably may avoid complications of PDT such as sub-retinal hemorrhag-
ing, exudative retinal detachments and choroidal vessel occlusion.1,3 In addition, recent studies have shown the 
efficacy of argon laser for PCV located outside of the foveal region and may be a potential treatment option for 
certain cases of PCV.6
This case demonstrates the importance of the appropriate diagnosis of a retinal condition that, at first glance, may 
be mistaken for exudative AMD. A correct diagnosis is critical for ensuring that the patient receives proper, timely 
care while avoiding unnecessary, costly and potentially harmful procedures. Readily available technology, such as 
OCT, can assist in making a correct diagnosis and help with monitoring for progression in an attempt to ensure a 
positive visual outcome for the patient. l
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